170 related articles for article (PubMed ID: 26033177)
1. Chemotoxicity recurrence in older patients: Risk factors and effectiveness of preventive strategies-a prospective study.
Extermann M; Reich RR; Sehovic M
Cancer; 2015 Sep; 121(17):2984-92. PubMed ID: 26033177
[TBL] [Abstract][Full Text] [Related]
2. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score.
Extermann M; Boler I; Reich RR; Lyman GH; Brown RH; DeFelice J; Levine RM; Lubiner ET; Reyes P; Schreiber FJ; Balducci L
Cancer; 2012 Jul; 118(13):3377-86. PubMed ID: 22072065
[TBL] [Abstract][Full Text] [Related]
3. Can older cancer patients tolerate chemotherapy? A prospective pilot study.
Chen H; Cantor A; Meyer J; Beth Corcoran M; Grendys E; Cavanaugh D; Antonek S; Camarata A; Haley W; Balducci L; Extermann M
Cancer; 2003 Feb; 97(4):1107-14. PubMed ID: 12569613
[TBL] [Abstract][Full Text] [Related]
4. Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial.
Brain EG; Mertens C; Girre V; Rousseau F; Blot E; Abadie S; Uwer L; Bourbouloux E; Van Praagh-Doreau I; Mourey L; Kirscher S; Laguerre B; Fourme E; Luneau S; Genève J; Debled M
Crit Rev Oncol Hematol; 2011 Oct; 80(1):160-70. PubMed ID: 21035352
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
6. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
[TBL] [Abstract][Full Text] [Related]
7. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Wolff D; Poniewierski MS; Dale DC; Crawford J; Lyman GH
Cancer; 2009 Nov; 115(22):5319-28. PubMed ID: 19672945
[TBL] [Abstract][Full Text] [Related]
8. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.
Di Maio M; Gallo C; Leighl NB; Piccirillo MC; Daniele G; Nuzzo F; Gridelli C; Gebbia V; Ciardiello F; De Placido S; Ceribelli A; Favaretto AG; de Matteis A; Feld R; Butts C; Bryce J; Signoriello S; Morabito A; Rocco G; Perrone F
J Clin Oncol; 2015 Mar; 33(8):910-5. PubMed ID: 25624439
[TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
Tibaldi C; Bernardini I; Chella A; Russo F; Vasile E; Malventi M; Falcone A
Clin Lung Cancer; 2006 May; 7(6):401-5. PubMed ID: 16800966
[TBL] [Abstract][Full Text] [Related]
10. Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer.
Wildes TM; Ruwe AP; Fournier C; Gao F; Carson KR; Piccirillo JF; Tan B; Colditz GA
J Geriatr Oncol; 2013 Jul; 4(3):227-34. PubMed ID: 23795224
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors for Chemotherapy-Related Toxicity and Adverse Events in Elderly Thai Cancer Patients: A Prospective Study.
Phaibulvatanapong E; Srinonprasert V; Ithimakin S
Oncology; 2018; 94(3):149-160. PubMed ID: 29212082
[TBL] [Abstract][Full Text] [Related]
12. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
13. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
[TBL] [Abstract][Full Text] [Related]
14. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
Balducci L; Falandry C; List A
Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
16. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Hamaker ME; Seynaeve C; Wymenga AN; van Tinteren H; Nortier JW; Maartense E; de Graaf H; de Jongh FE; Braun JJ; Los M; Schrama JG; van Leeuwen-Stok AE; de Groot SM; Smorenburg CH
Breast; 2014 Feb; 23(1):81-7. PubMed ID: 24314824
[TBL] [Abstract][Full Text] [Related]
17. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
Takagi Y; Hosomi Y; Oshita F; Okamoto H; Seki N; Minato K; Aono H; Yamada K; Okuma Y; Hida N; Sakamoto T; Miura Y; Yomota M; Satoh A; Kunitoh H; Sakamaki K; Shibuya M; Watanabe K
BMC Cancer; 2015 Oct; 15():740. PubMed ID: 26481215
[TBL] [Abstract][Full Text] [Related]
18. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Pujol JL; Paz-Ares L; de Marinis F; Dediu M; Thomas M; Bidoli P; Corral J; San Antonio B; Chouaki N; John W; Zimmermann A; Visseren-Grul C; Gridelli C
Clin Lung Cancer; 2014 Nov; 15(6):418-25. PubMed ID: 25104617
[TBL] [Abstract][Full Text] [Related]
19. Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.
Montemurro F; Mittica G; Cagnazzo C; Longo V; Berchialla P; Solinas G; Culotta P; Martinello R; Foresto M; Gallizioli S; Calori A; Grasso B; Volpone C; Bertola G; Parola G; Tealdi G; Giuliano PL; Aglietta M; Ballari AM
JAMA Oncol; 2016 Apr; 2(4):445-52. PubMed ID: 26720497
[TBL] [Abstract][Full Text] [Related]
20. Predicting chemotherapy toxicity in older adults with lung cancer.
Nie X; Liu D; Li Q; Bai C
J Geriatr Oncol; 2013 Oct; 4(4):334-9. PubMed ID: 24472476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
